Gilead And GSK To Bring Viread To China
This article was originally published in PharmAsia News
Executive Summary
China, with over 280 million sufferers of hepatitis B, will become the site of clinical trials for a new treatment stemming a joint venture of Gilead Sciences and GlaxoSmithKline